Close Menu

AbD Serotec

This story has been updated from a previous version to include comments from Bio-Rad's earnings call.

NEW YORK (GenomeWeb News) - Bio-Rad Laboratories said today that it has closed its acquisition of antibody manufacturer AbD Serotec, a division of MorphoSys, for around €53 million ($70 million) in cash.

NEW YORK (GenomeWeb News) – Bio-Rad Laboratories announced yesterday that it has signed a definitive agreement to acquire antibody manufacturer AbD Serotec for €53 million ($69.7 million) in cash.

Morphosys said it has agreed to a three-year extension of its ongoing research partnership with Japanese pharma firm Shionogi.

Morphosys announced that its AbD Serotec division has signed an agreement with the Moredun Research Institute and the University of Edinburgh's Roslin Institute to develop reagents for veterinary research.

The agreement grants Merck access to the company's HuCAL Gold antibody library for research purposes, as well as the option to upgrade to Morphosys's HuCAL Platinum library.

Researchers have developed a robotic lab assistant, the Verge reports.

CBC News reports Canada's Supreme Court is to rule on the constitutionality of the country's genetic non-discrimination law today.

The Associated Press reports the World Health Organization is sending experts to China to investigate the animal source of SARS-CoV-2.

In Science this week: atlas of affected cell populations in idiopathic pulmonary fibrosis, and more.